What is Halozyme Therapeutics's AOCI?

Halozyme Therapeutics (HALO) reported AOCI of -$12.7M in Q1 2026.

How has Halozyme Therapeutics's AOCI changed year-over-year?

Halozyme Therapeutics's AOCI decreased by 272.2% year-over-year, from -$3.41M to -$12.7M.

What is the long-term trend for Halozyme Therapeutics's AOCI?

Over 5 years (2020 to 2025), Halozyme Therapeutics's AOCI has grown at a 282.8% compound annual growth rate (CAGR), from $22K to -$18.09M.

Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.

Halozyme Therapeutics HALO AOCI

AOCI at other companies

West Pharmaceutical ServicesWST

-$125.2M+39.1%

BridgeBio PharmaBBIO

-$8K—

Arrowhead ResearchARWR

$742K-83.1%

AptarGroupATR

-$198.72M+43.4%

AbbVieABBV

-$1.15B+33.8%

AlkermesALKS

-$2.91M-99.9%

Other financials

Income statement

See full

Revenue$376.7M+42.2%

Gross profit$297.5M+37.4%

Operating income$184.5M+30.4%

Net income$150.0M+27.1%

EPS (diluted)$1.22+31.2%

Balance sheet

See full

Cash & equivalents$312.0M+76.9%

Total debt$2.2B+41.7%

Total equity$219.6M-54.5%

Total assets$2.7B+21.7%

Cash flow

See full

Operating cash flow$180.1M+16.8%

CapEx$3.7M+294%

Free cash flow$176.3M+15.0%

Valuation

See full

Market cap$8.13B-2.9%

Enterprise value$10B+3.0%

P/E13.4×-3.8×

P/S5.4×-2.3×

Profitability

See full

Gross margin82.8%-0.7pp

Operating margin59.3%+9.0pp

Net margin47.9%+6.5pp

FCF margin44.3%-1.5pp

Returns & leverage

See full

Return on equity124.5%+12.7pp

Debt / equity9.9×+6.7×

Current ratio2.8×-5.6×

Where this comes from

Reported directly by Halozyme Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.

The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Halozyme Therapeutics's aoci.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Halozyme Therapeutics's AOCI?: Halozyme Therapeutics (HALO) reported AOCI of -$12.7M in Q1 2026.
How has Halozyme Therapeutics's AOCI changed year-over-year?: Halozyme Therapeutics's AOCI decreased by 272.2% year-over-year, from -$3.41M to -$12.7M.
What is the long-term trend for Halozyme Therapeutics's AOCI?: Over 5 years (2020 to 2025), Halozyme Therapeutics's AOCI has grown at a 282.8% compound annual growth rate (CAGR), from $22K to -$18.09M.
What does AOCI mean?: Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.